ProCE Banner Activity

CheckMate 358: Phase I/II Evaluation of Nivolumab Monotherapy in Virus-Associated, Recurrent/Metastatic Gynecologic Cancers

Slideset Download
Conference Coverage
Nivolumab monotherapy active with a manageable safety profile in recurrent/metastatic cervical, vaginal, or vulvar cancer regardless of PD-L1 expression.

Released: June 04, 2017

Expiration: June 03, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology